Endogenous HLA-DQ8αβ programs superantigens (SEG/SEI) to silence toxicity and unleash a tumoricidal network with long-term melanoma survival
Background As the most powerful T cell agonists known, superantigens (SAgs) have enormous potential for cancer immunotherapy. Their development has languished due to high incidence (60%–80%) of seroreactive neutralizing antibodies in humans and tumor necrosis factor-α (TNFα)-mediated cardiopulmonary...
Saved in:
| Main Authors: | David Bradley, Peter Knopick, David Terman, Nathan Riha, Travis Alvine, Riley Larson, Cedric Badiou, Gerard Lina, John Ballantyne |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e001493.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A naturally selected αβ T cell receptor binds HLA-DQ2 molecules without co-contacting the presented peptide
by: Jia Jia Lim, et al.
Published: (2025-04-01) -
The incidence of HLA-DQ2/DQ8 in Turkish children with celiac disease and a comparison of the geographical distribution of HLA-DQ
by: Ahmet Basturk, et al.
Published: (2017-12-01) -
Understanding HLA-DQ in renal transplantation: a mini-review
by: Rajdeep Das, et al.
Published: (2025-02-01) -
ASSOCIATION OF HLA-DQ POLYMORPHISMS WITH HEPATITIS B VIRUS INFECTION IN TURKISH POPULATION
by: Bülent Çakal, et al.
Published: (2022-10-01) -
Association between HLA-DQ Gene Polymorphisms and HBV-Related Hepatocellular Carcinoma
by: Jingzhu Lv, et al.
Published: (2017-01-01)